Does Medicare Cover Wegovy?

For two decades, the answer to Does Medicare cover Wegovy? was a flat no, no asterisk needed. Then the SELECT trial happened, and Novo Nordisk filed a supplemental FDA application, and the FDA approved a new indication, and CMS issued a memo, and now the answer is the messiest kind of maybe — the kind where you have to read the fine print on your own plan’s formulary and check your medical records before you’ll know what you’ll pay.

If you’ve heard people say “Medicare started covering Wegovy in 2024,” that’s almost true. What actually happened is narrower and more conditional than the headlines suggested.

The coverage shift, in plain terms

In March 2024, the Centers for Medicare & Medicaid Services issued guidance that changed how Part D plans can treat anti-obesity medications when those drugs have an additional FDA-approved indication beyond weight loss. Specifically: when a drug like Wegovy receives FDA approval for a non-cosmetic medical purpose — in this case, reducing the risk of cardiovascular events in patients with overweight or obesity and established cardiovascular disease — Part D plans are now permitted to cover it for that indication.

The key word is permitted, not required. CMS opened the door. Each plan decides whether to walk through it.

The trigger for this guidance was the SELECT trial, published in The New England Journal of Medicine in late 2023, which showed that Wegovy reduced major adverse cardiovascular events by about 20 percent in patients with established cardiovascular disease and overweight or obesity who did not have diabetes. Based on those results, the FDA expanded Wegovy’s label to include cardiovascular risk reduction in March 2024. CMS’s coverage memo followed within weeks.

Who actually qualifies under the new rules

To have a real shot at coverage, three things need to be true:

1. Your plan covers Wegovy for the cardiovascular indication. Not all Part D plans do. Some major carriers added it for the 2025 plan year; others held back, citing budget impact. Check your plan’s formulary.
2. You have established cardiovascular disease. This typically means documented history of a heart attack, stroke, transient ischemic attack, peripheral artery disease, or coronary artery disease confirmed by imaging, stenting, or bypass surgery. Plans expect to see this in your charts.
3. You have overweight or obesity. The label uses BMI of 27 or higher with weight-related comorbidities, or BMI of 30 or higher.

If all three boxes check, your prescriber submits a prior authorization, and the plan should approve coverage. You’ll then pay your plan’s Tier 3 (or specialty tier) copay until you hit the new $2,000 annual out-of-pocket cap on Part D drugs.

What you’ll pay if you’re covered

Wegovy on a covered plan typically lands on Tier 3 — the preferred-brand tier — though some plans place it on Tier 4 or even specialty Tier 5. Your monthly cost depends entirely on tier placement and your phase of the Part D benefit:

• Deductible phase: Most plans now apply some level of deductible, capped at $590 in 2026. During the deductible, you pay the negotiated price, which for Wegovy is roughly $1,000 to $1,200 per fill.
• Initial coverage phase: After meeting the deductible, you pay your tier copay — typically $40–$100 on Tier 3, or 25–33% coinsurance if it’s placed on a specialty tier.
• Catastrophic phase ($0): Once your true out-of-pocket spending reaches $2,000 in the calendar year — a cap that started in 2025 — you pay $0 for the rest of the year on covered Part D drugs.

For most Wegovy users meeting the cardiovascular criteria, the year shakes out to roughly $2,000 in out-of-pocket spend, hit somewhere between February and May depending on tier placement and other concurrent prescriptions.

What you’ll pay if you’re not

The cash market for Wegovy runs about $1,300 to $1,600 per 28-day supply at major retail pharmacies. Costco, Walmart, and a handful of online pharmacies routinely come in $100–$200 lower than independents. There is no Medicare workaround for the cash price; the manufacturer savings program excludes anyone with Medicare or Medicaid coverage by federal law.

Some patients pay cash for Wegovy, then switch to a covered alternative once they’ve achieved enough weight loss to address the underlying issue. Others use a compounded semaglutide product from a 503A or 503B compounding pharmacy at lower cost — though as of late 2024, the FDA has begun moving against compounded semaglutide because Wegovy is no longer in shortage, and many compounders have stopped offering it. This is a moving target; talk to your prescriber about the current legal status before relying on a compounded product.

The diabetes vs. weight-loss distinction (and why Ozempic still matters)

Wegovy and Ozempic are the same active ingredient — semaglutide — at different doses with different FDA-approved indications. From Medicare’s perspective they’re not interchangeable.

If you have type 2 diabetes, your prescriber can write Ozempic, and Part D will almost certainly cover it as a diabetes drug. If you have obesity but not diabetes, Wegovy is the labeled product, and coverage hinges on whether you also have established CVD.

It would be tempting to ask, “Why not just have my doctor prescribe Ozempic for diabetes?” The answer is that most Part D plans won’t approve Ozempic without documented type 2 diabetes — usually evidenced by an A1c above 6.5%. Without that, the prior authorization will be denied. Manipulating diagnosis codes is also fraud, with real consequences for the prescriber.

How to navigate prior authorization

For Wegovy under the cardiovascular indication, expect a thorough PA process:

• Your prescriber’s office submits a prior authorization form to your Part D plan.
• The form must document the cardiovascular diagnosis with ICD-10 codes (commonly I21 for prior MI, I63 for prior stroke, I25 for ischemic heart disease, I73.9 for PAD).
• Many plans want a documented BMI from a recent visit and a brief clinical justification.
• Plans typically respond within 72 hours; expedited reviews exist for urgent situations.

If denied, the appeal pathway is the one to know. CMS data consistently shows that Part D coverage denials are reversed on appeal at meaningful rates, particularly when the prescriber submits a thorough redetermination request with documentation. Don’t accept a denial as the final word — file the appeal.

The bigger picture: where Medicare obesity coverage is heading

Wegovy’s partial coverage is the biggest crack in Medicare’s anti-obesity drug exclusion in the program’s history. It exists because Wegovy successfully argued — through clinical trial data — that it’s not just an obesity drug; it’s a cardiovascular drug for a specific population.

Other GLP-1s and obesity drugs are pursuing similar paths. Eli Lilly’s Zepbound (the weight-loss labeled version of Mounjaro) is running cardiovascular outcomes trials. If Zepbound demonstrates similar benefit, expect a parallel CMS expansion within a year of any new FDA indication.

Whether Medicare will eventually cover obesity drugs broadly is a separate question, and it’s a legislative one. The Treat and Reduce Obesity Act has been introduced in every Congress for over a decade without passage. Industry, patient advocacy groups, and the obesity-medicine specialty are pushing hard. Until something passes, Wegovy and its conditional cardiovascular indication is the only door that’s open — and only for the patients who fit the door’s narrow shape.

Bottom line

Wegovy is covered by Medicare Part D, but the coverage door is narrow: established cardiovascular disease plus overweight or obesity, on a plan that has elected to add the drug to its formulary, after a successful prior authorization. Each of those four conditions is non-trivial. Take the time to confirm each before you start treatment, because the cash price for Wegovy without coverage is high enough to derail a household budget.